Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced to adopt the RenMice® series as the collection name for the Company's independently developed, fully human antibody mice and TCR mice with proprietary intellectual property. The RenMice® series encompasses five strains of fully human antibody/TCR mice: RenMab®, RenLite®, RenNano®, RenTCRTM, and RenTCR-mimicTM. These mice provide support for the discovery of fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies.

The Company is also generating more strains of fully human RenMice for major histocompatibility complex (MHC) cluster genes, natural killer cell (NK cell) cluster genes, and other gene clusters for diverse drug development purposes, which will be integrated into the RenMice® series upon successful development. Since their successive release in 2019, RenMice® series has received global recognition in the biopharmaceutical field. As of June 30, 2023, Biocytogen has entered into RenMice licensing agreements with 20 biopharmaceutical/biotechnology companies, including several partnerships with multinational pharmaceutical companies; 42 target-nominated antibody development projects have been initiated.

After the initiation of Project Integrum, 50 therapeutic antibodies co-development/out-licensing/transfer agreements have been established. As Project Integrum has completed approximately 1,000 target-specific antibody discovery projects as a milestone in progress, the number of external therapeutic antibody co-development/out-licensing/transfer agreements are expected to increase significantly. In the future, the Company will continue to research and develop RenMice® series mice with different genetic backgrounds to meet the needs of drug development for different targets.

Meanwhile, the development of fully human mice for MHC, NK cell and other gene clusters is in progress. The successful development of new technology platforms will further enhance Biocytogen's technical capabilities in drug discovery and accelerate the development of new therapeutics in collaboration with global partners, benefiting human health.